A $40 million investment agreement in Moroccan health technology looks straightforward until you read the regulator’s notice. ABA Life, the healthcare arm of ABA Technology, announced the deal with pan-African investor Admaius Capital Partners on 26 October 2026. But the investment has not yet completed, and its proposed ownership structure is more consequential than a routine minority funding announcement.
Morocco’s Competition Council notice dated 29 October identifies the proposed investor as Virunga Genesis Ltd, a Rwandan vehicle indirectly controlled by a fund advised by Admaius. It describes the transaction as an acquisition of joint control over ABA Life alongside current owner ABA Technology.
The distinction is deliberate: signing an investment agreement is not the same as receiving final regulatory approval and closing the transaction.
How the investment would work
The notified structure involves Virunga subscribing to new shares through reserved capital increases, rather than merely buying an existing shareholder’s shares. In that form, fresh equity is intended to enter ABA Life itself if the transaction closes.
The company’s release distributed through Wamda describes the investment as $40 million, subject to customary conditions and competition clearance. Moroccan reporting also cites roughly 400 million dirhams. These are representations of the same transaction, not two separate funding commitments.
Le Desk reported that management expected Admaius’s economic stake to be around 12% to 14%, with the precise level dependent on the company’s 2026 results. A proposed joint-control arrangement can contain governance rights beyond the percentage of shares held, so the reported stake and the regulator’s description are not necessarily contradictory.
Why a healthtech company attracts private equity
ABA Life operates in connected healthcare, telemedicine and medical infrastructure, including mobile medical units. It says its model combines technology with the delivery of clinical services, and that it has become profitable. Those profitability claims are attributable to the company, not an independent audit available in the transaction notice.
The planned proceeds would finance its AI for Sovereign Health programme, technology industrialisation and international expansion. In practical terms, this is a capital-intensive proposition. Software for clinical decision support is one component; medical devices, deployments, training, service support and institutional contracts can absorb much more capital.
That helps explain a growth-equity investor’s interest. It is also why execution needs scrutiny. A system used in healthcare must work in real clinical settings, protect patient information and provide credible evidence of safety and usefulness. No investment announcement establishes those outcomes by itself.
The regulatory clock is still running
The Competition Council has invited third-party comments until 9 November 2026. Its notice expressly says the transaction summary was supplied by the parties and does not represent an approval. As of this article’s preparation, we have not verified a final clearance decision.
The story to follow is therefore not a claimed completed $40 million fundraise or a guaranteed Moroccan unicorn. It is whether the proposed capital increase closes, what governance rights the investor receives and which healthcare deployments it actually finances.
If those answers emerge, this could become a substantial African healthtech expansion case. For now, it remains a signed, conditional investment with an unusually clear public regulatory trail.






